News

March 4, 2021March 4, 2021

Actemra Injections for sJIA, pJIA Easier Than Comparable Infusions

News

Compared with an infusion into the vein, injecting Actemra (tocilizumab) under the skin offers people with systemic and polyarticular juvenile idiopathic arthritis (JIA) similar performance in a more convenient route ... Read more

February 25, 2021February 25, 2021

UK Group Awarded £600K to Study Juvenile Arthritis, Related Disorders

News

Versus Arthritis has funded three more years of research into therapies for juvenile arthritis and related conditions at the U.K. Experimental Arthritis Treatment Centre for Children (EATC4Children) with a £600,000 ... Read more

February 18, 2021February 18, 2021

Yuflyma, Biosimilar of Humira, Approved for Use in Europe

News

The European Commission (EC) has approved Yuflyma (CT-P17), an adalimumab biosimilar, to treat multiple chronic inflammatory diseases, including juvenile idiopathic arthritis. Similar to generics, biosimilars are products that have identical ... Read more

February 11, 2021February 11, 2021

Genetic Signature May Identify sJIA Children Who Respond to Ilaris

News

A specific genetic signature can help in identifying children with systemic onset juvenile arthritis (sJIA) who are most likely to respond well to Ilaris (canakinumab), a study suggests. Children with ... Read more

February 4, 2021February 4, 2021

Uveitis Leads to Poorer Vision in JIA Children, Affecting Life Quality

News

Uveitis, a form of eye inflammation, worsens vision and vision-related quality of life among children with juvenile idiopathic arthritis (JIA), according to a large questionnaire study. Results also showed worse ... Read more

January 28, 2021January 28, 2021

Advocacy Groups Team Up to Fund World’s Largest JIA Register

News

Versus Arthritis and the British Society for Rheumatology have partnered to share data — and to fund the UK JIA Register, which will track the long-term safety and efficacy of ... Read more

January 21, 2021January 21, 2021

Celecoxib Capsules, Generic of Celebrex, Approved for Pain, Inflammation

News

The U.S. Food and Drug Administration (FDA) has approved celecoxib capsules — a generic form of Pfizer’s Celebrex — to treat inflammation and pain in juvenile idiopathic arthritis (JIA) and ... Read more

January 14, 2021January 14, 2021

Disease Activity in Black Children with pJIA Higher Than in Whites, Study Shows

News

Use of a treat-to-target approach, combined with a tool to support clinical decisions, significantly lowered disease activity in children with polyarticular juvenile idiopathic arthritis (pJIA) regardless of race and disease duration, ... Read more

January 7, 2021January 7, 2021

Methotrexate, Humira Seen to Alter Immune Cell Counts in JIA Children

News

Significant changes were found in the immune cell levels of children with juvenile idiopathic arthritis (JIA) following treatment with methotrexate and Humira (adalimumab), a study reports. These findings help explain ... Read more

December 17, 2020December 17, 2020

JIA Patients Show Differences That May Affect Future Disease Activity, Study Says

News

An analysis using machine learning identified distinct patient groups and disease activity trajectories among young patients in the U.K. with juvenile idiopathic arthritis (JIA). Its findings revealed that nearly a quarter of ... Read more